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Editorial
The Post-MADIT II Era: ICD for all Post-infarct Patients with
Moderate to Severe Left Ventricular Dysfunction?
KATHY LAI-FUN LEE, CHU-PAK LAU
From Cardiology Division, University Department of Medicine, Queen Mary Hospital, Hong Kong
Device therapy has become the preferred
treatment for patients who have survived sudden cardiac
death. Throughout the last decade, large-scale
randomized clinical trials have provided consistent
evidence on the clinical efficacy of device therapy. ICD
is proven to be superior to anti-arrhythmic drugs in
patients with structural heart diseases who suffer from
haemodynamically significant ventricular arrhythmias.
The role of ICD in primary prevention of sudden death
in selected patients with coronary artery disease and left
ventricular dysfunction is also widely established after
the Multicenter Automatic Defibrillator Implant Trial
(MADIT)1 and the Multicenter Unsustained Tachycardia
Trial (MUSTT).2
In MADIT, patients with previous myocardial
infarction, depressed left ventricular function (ejection
fraction <35%) and non-sustained ventricular
tachycardia underwent electrophysiology study. Among
them, 196 patients with inducible sustained ventricular
tachyarrhythmias but not suppressed by procainamide
were randomized to receive an ICD or conventional
therapy. The ICD group had a 54% reduction in mortality
at 2 years, and the benefit was greatest in patients with
the lowest left ventricular ejection fraction. The MUSTT
trial was designed to compare electrophysiology-guided
therapy and no active treatment in high-risk patients with
Address for reprints: Dr. Kathy Lai-Fun Lee
University Department of Medicine, Queen Mary Hospital, 102
Pokfulam Road, Hong Kong
Tel: (852) 2855 3633, Fax: (852) 2818 6304
Opinions expressed are views of the authors and not necessarily
the view of the editorial board or the Hong Kong College of
Cardiology.
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asymptomatic non-sustained ventricular tachycardia.
The 2,202 patients with previous myocardial infarction
and ejection fraction of 40% or less underwent
electrophysiology study before randomization. The noninducible patients (65%) were followed-up in the
registry. The 704 inducible patients (35%) were
randomized to receive conventional therapy with no
antiarrhythmics or electrophysiologically guided
treatment. Patients who remained inducible despite class
IA antiarrhythmics, propafenone, or sotalol were
randomized to ICD or further drug testing until all
patients received either an ICD or an effective drug. At
5 years of follow-up, mortality was 9% in patients who
received ICD, 34% in patients treated with an effective
drug guided by electrophysiology study, and 32% in
patients randomized to no antiarrhythmics. The MUSTT
trial confirmed that post-infarct patients with depressed
left ventricular function and non-sustained ventricular
tachycardia were at high risk for arrhythmic death, and
ICD was superior to both electrophysiologically guided
therapy and no active treatment.
Both the MADIT and MUSTT trials studied the
effect of device therapy in selected high-risk post-infarct
populations. Apart from left ventricular dysfunction,
non-sustained ventricular tachycardia and inducibility
at electrophysiology study were key eligible criteria. To
go one step further, in MADIT II, patients with prior
myocardial infarction and an ejection fraction of 30%
or less were studied.3 The result of this landmark ICD
primary prevention trial was announced in the Annual
Scientific Session of the American College of
Cardiology this year. Among 1,232 patients with prior
myocardial infarction (more than 1 month) and left
ventricular ejection fraction of 30% or less were
randomized to receive an ICD or conventional medical

July 2002

98

THE POST-MADIT II ERA

therapy in a 3:2 ratio. No non-sustained ventricular
arrhythmias or electrophysiology study was required for
enrollment. During an average follow-up of 20 months,
the mortality in the ICD group was 14.2% and that of
the control group was 19.8%. This study demonstrated
that prophylactic ICD offered significant survival benefit
in patients with advanced left ventricular dysfunction
after myocardial infarction. Subgroup analysis showed
that the benefit was greater in patients with age less than
60 years or QRS duration more than 0.15 sec.
There is robust evidence to support that
prophylactic device therapy offers survival benefit to
patients at high risk of sudden death. However, this
therapy is not entirely free of complications. The cost
involved is also substantial. In the US, it is estimated
that there are approximately 400,000 new MADIT IIalike patients annually. In Hong Kong, if 10% postinfarct patients become eligible for ICD because of the
MADIT II data, there will be approximately 300 more
implants yearly (Hong Kong Acute Myocardial
Infarction Registry data, 1995). The annual cost is nearly
50 million dollars, an amount that is greater than the
total sales value of all the ACE inhibitors and AII
antagonists used in Hong Kong last year. This does not
take into account the cost of replacement of these devices
that have an average longevity of 5 years. When the
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result of the ongoing cost-effectiveness analysis is
available, we may have a better picture of how practical
it is to apply the MADIT II evidence in our clinical
practice. In the long run, it is anticipated that market
force and competition may eventually drive down the
cost of ICD. In the mean time, prophylactic ICD
implantation should be seriously considered in patients
with prior myocardial infarction and advanced left
ventricular dysfunction, especially in those with a
younger age or a wide QRS complex on surface
electrocardiogram.
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Predictor of High-Risk Patients after Acute Myocardial Infarction
by Serial Echocardiography
GAO-XING ZHANG*, XUE-DONG SHEN**, SHOU-YUE PU**, HAO-ZHU CHEN**
From *Jiangmen Central Hospital, Guangdong Province, Jiangmen 529071, China; **Shanghai Institute of
Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China

ZHANG ET AL.: Predictor of High-Risk Patients after Acute Myocardial Infarction by Serial Echocardiography.
In order to distinguish between the low and high-risk patients for ventricular remodeling after acute myocardial
infarction (AMI) and to determine whether an early predictor of progressive ventricular dilatation and chronic
dysfunction could be identified, 70 consecutive patients undertook serial echocardiography on the entry, 3 days, 2
weeks, 3 and 6 months after admission. The results showed that variables influencing the pattern of remodeling are
the location of AMI, initial endocardial surface area index and abnormal wall motion area and reperfusion of
infarcted-related artery. Increased endocardial surface area index within 48 hours of onset of AMI can be considered
as an echocardiographic manifestation of infarct expansion, and was proposed an early predictor for high risk
patients after AMI. (J HK Coll Cardiol 2002;10:100-104)
Echocardiography, Myocardial infarction, Ventricular remodeling
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Introduction
Two dimensional echocardiography has become
established as an ideal noninvasive method to identify
and quantitate regional left ventricular morphology that

Address for reprints: Dr. Gao-Xing Zhang
Jiangmen Central Hospital, Guangdong Province, Jiangmen
529071, China
Tel: (750) 3396236, Fax: (750) 3375441
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accompanies acute myocardial infarction (AMI).1,2 A
number of studies have emphasized the acute structure
and functional changes were dynamic and varied with
the size and location of the infarction. In addition,
dilatation of the left ventricle might play an important
and active role in the development of chronic heart
failure, and left ventricular volume was the most
powerful predictor of survival in patients with coronary
artery disease.3 Deterioration of cardiac performance
correlated with the degree of dilatation in patients with
AMI. However, the time course and interaction of
regional function of noninfarcted and infarcted
myocardium and global left ventricular dysfunction had
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not been evaluated in detail. The purpose of this study
was to use computerized echocardiography to
prospectively determine the natural history of left
ventricular size, area of abnormal wall motion (AWM),
i.e. area of functional infarct size, and ventricular
function, to distinguish between the low and high risk
patients for ventricular remodeling from entry until
6 months after AMI, and to determine whether an early
predictor of progressive ventricular dilatation and
chronic dysfunction could be identified.

Two dimensional echocardiography was
performed prospectively with a 2.5 mHZ transducer
using a phased array system (HP1000 or HP2500) by
one sonographer at entry, 3 days, two weeks, 3 and 6
months after first AMI. Echocardiographic images of
the left ventricle were obtained from five standard
imaging planes-parasternal short axis views at mitral
valve, papillary muscles and apical level as well as
apical four chamber and two chamber views.

Measurement of Endocardial Surface Area
Index of Left Ventricle and AWM

Materials and Methods
Study Group
Patients with a first Q wave AMI were
prospectively screened for inclusion into the study. Q
wave AMI was defined by the presence of chest pain
lasting at least 30 minutes, new ST segment elevation
in ECG, appearance of new Q waves on serial
electrocardiograms, and a significant rise in creatine
kinase (CK) and cardiac isoenzyme fraction (CK-MB).
Patients with previous myocardial infarction, primary
valvular heart disease, cardiomyopathy, the onset of
symptoms more than 48 hours before entry were
excluded from the study. In addition, patients with
echocardiogram of inadequate quality for quantitative
analysis were also excluded. Seventy of the 73 patients
completed the study, including 3 patients not being
followed up (follow-up rate 95.4%), Eight patients
(7 anterior and 1 inferior; mean age 64±6.2 years) died
during follow-up (11%). Six months follow-up were
completed in 62 patients, 42 of that had anterior
infarction, 20 had inferior infarction (male 50 and female
12, mean age 59±11.6 years). Patients were in hospital
within 12 hours after disease onset and treated with
thrombolytic therapy. Sixteen (11 anterior and 5 inferior,
mean age 59.8±10.1 years ) of 62 patients had patency
of infarct-related coronary artery, which was assessed
by uniform clinical criteria (receiving thrombolytic
therapy) or by coronary angiography (receiving coronary
angioplasty or/and coronary stents). Thirty normal
volunteers served as normal controls. This group
consisted of 22 men and 8 women (mean age 60.9±15.3
years). Twenty-four of the 70 patients had cardiac events
such as cardiogenic death, persistent ventricular
tachycardia, ventricular fibrillation, symptomatic heart
failure and post-infarction angina pectoris.
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Data Acquisition of Echocardiography

Suitable images from the five recorded planes
(three short axis views, two and four chamber views)
were used to derive the cardiac dimensions including
long axis and endocardial length of left ventricle, and
the endocardial length of abnormal wall motion segment.
The endocardial surface area of left ventricle and AWM
area were calculated with a computerized data process
system reported and validated previously.4,5 Because
body surface area has been identified as a primary
determinate of normal left ventricular dimensions, the
endocardial surface area of left ventricle was corrected
for the body surface area. This corrected endocardial
surface area, i.e., ESAi, and AWM area were used in
analyses for between-patients comparisons.

Standards of Ventricular Size
Thirty normal volunteers without coronary artery
disease were used as controls. This group, mean age
60.9±15.3 years, consisted of 22 man and 8 women. The
mapping technique was then applied to generate a
normal range for endocardial surface area. The range of
normal ESAi was 63.7±5.1 cm2/m2. An ESAi of more
than 2 standard deviation above the control group were
defined as ventricular enlargement.

Standards of Infarct Expansion
Infarct expansion was defined as left ventricular
enlargement, wide-mouthed, thinned-walled myocardial
segments that display dyskinetic expansion during systole.

Statistic Analysis
Data were expressed as mean±SD. Statistical
comparisons between groups were made by analysis of
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variance (ANOVA). Comparisons of frequency of
events were performed by x2 analysis.

Results
Serial Echocardiographic Quantitative Analysis
After AMI, the changes of left ventricle and the
infarct area had different trends during 6 months. The
effects on left ventricular ejection fraction (EF) value
(measured by Simpson's equation) were also different.
Based on the data shown in Table 1, patients were
divided into four subgroups: (1) 20 had a normal ESAi
on admission, no changes during 3 months after AMI,
a decrease in left ventricular size at 6 months (P<0.05).
Decrease in infarct area was noted from entry to
6 months after AMI (P<0.01), without EF reduced; (2)
27 had progressive left ventricular dilatation from entry
to 3 months after AMI (P<0.05), decreased in left
ventricular size and infarct area from 3 to 6 months
(P<0.01), and reduction in EF value (P<0.01); (3) 15
had limited dilatation with subsequent reduction.
Whether left ventricular dilatation or not at entry, no

change in ESAi at two weeks, but decrease in the left
ventricular size noted from 2 weeks to 6 months after
AMI, and progressive decrease in infarct area from entry
to 6 months, without significant reduction in EF value;
(4) 7 had an enlarged ESAi at entry, accelerated left
ventricular dilatation within 72 hours after AMI. All
the patients had infarct area extended greatly with
typical manifestation of infarct expansion, and large
reduction in EF value. Those 8 patients died in hospital
except one were all in this pattern.

Influencing Factors of Ventricular Remodeling
after AMI
Based on the size of infarct area, ESAi within 48
hours after AMI and early reperfusion, various
remodeling process could be analyzed as follows: In
the patients with no dilatation of left ventricle, AWM
area was the smallest. Most of them had inferior AMI.
Left ventricular size was unchanged except in two
patients (ESAi=74 cm2/m2). Six of the 20 patients had
early reperfusion.
In the group with progressive dilatation of left
ventricle, most patients had anterior AMI, 12 of whom

Table 1. Natural history of ESAi, area of AWM, and EF value
Time
ESAi
24 hours
72 hours
2 weeks
3 months
6 months
AWM area
24 hours
72 hours
2 weeks
3 months
6 months
EF
24 hours
72 hours
2 weeks
3 months
6 months

Group 1
n=20

Group 2
n=27

Group 3
n=15

Group 4
n=7

66.5±5.5
67.7±6.3
69.5±8.6
65.5±9.0
62.1±7.5*

73.8±8.2
76.6±9.2
77.3±8.4
79.6±9.4*
69.9±7.9##

72.5±11.2
74.3±11.0
71.1±8.7
65.2±7.9*
61.8±6.7**

79.4±9.2
91.1±7.7*

24.7±3.2
24.6±3.1
22.6±4.2
20.4±4.9**
17.0±4.8#

55.3±12.6
56.0±13.7
56.8±14.4
61.0±15.5
43.2±9.9 **##

55.1±9.0
54.1±9.6
46.0±7.0**
42.9±7.0
38.5±7.1**

66.4±11.3
79.7±10.3*

0.47±0.05
/
0.48±0.06
0.47±0.07
0.52±0.06

0.45±0.07
/
0.44±0.08
0.44±0.05
0.39±0.07**##

0.47±0.05
/
0.47±0.08
0.48±0.06
0.51±0.06

0.42±0.01
0.34±0.08*

Group 1: LV no changes; group 2: progressive dilatation; group 3: progressive decreased; group 4: accelerated ventricular dilatation
*compared with at entry P<0.05, **compared with at entry P<0.01; #compared with at 3 months P<0.05, ##compared with at 3 months P<0.01
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had initial left ventricular dilatation at entry, with AWM
area larger than those without initial dilatation
(P<0.001).
In patients with progressive decrease in size of
left ventricles in the presence of anterior AMI, 7 patients
had initial dilatation, with AWM area larger than those
without initial dilatation (P<0.001). All patients had
early reperfusion.
All seven patients with accelerated left ventricular
dilatation within 72 hours after AMI had initial dilatation
and anterior AMI. None had early reperfusion, but they
had the most significant left ventricular dilatation and
the largest AWM area. The initial left ventricular size
and AWM area between progressive dilatation group
and progressive decrease group had no significant
difference.

Influence on Cardiac Function and Prognosis by
Ventricular Remodeling
Patients with accelerated ventricular dilatation in
72 hours after AMI had the lowest initial EF value at
entry (P<0.05), which continued to further decrease
within 72 hours of onset of AMI. Seven of those patients
were dead in hospital. Six months after AMI, EF value
in progressive dilatation group was the lowest and
differed significantly from the other two groups
(P<0.05). EF value was much lower in patients with
initial dilatation than without initial dilatation (P<0.01).
Twenty-four of the 70 patients had cardiac events,
including 7 patients with accelerated ventricular
dilatation within 72 hours after AMI, 14 patients with
progressive ventricular dilatation , 2 patients with no
ventricular dilatation, and 1 patient with progressive
ventricular size reduction. There were 19 patients with
anterior AMI with initial dilatation but without early
repefusion at entry (12 from ventricular progressive
dilatation group, 7 from accelerated ventricular
dilatation group), 15 of which had cardiac events (7
died in hospital, 3 had persistent ventricular tachycardia,
6 had symptomatic heart failure, 1 had post-infarction
angina pectoris).

Discussion
Significance of Discrimination of Left
Ventricular Remodeling by Echocardiography
Our study demonstrated that there were various
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manifestations of ventricular remodeling, such as no
significant changes in ventricular size, progressive
dilatation, limited dilatation with subsequent reduction
and accelerated ventricular dilatation in 72 hours, which
had different effects on left ventricular function and
prognosis. The infarct size was critical to ventricular
remodeling. Patients with larger anterior infarct area
tended to have the higher risk of infarct expansion and
progressive dilatation, while those who had smaller
infarct areas of inferior infarction had the lower
tendency. Measurement of ESAi and AWMA area by
echocardiography could serially assess the process of
ventricular remodeling accurately, and distinguish
between the low and high risk patients for ventricular
remodeling for intervention. Variables influencing the
pattern of remodeling were the location of AMI, initial
ESAi and AWMA size and reperfusion of infarct-related
artery.

Assessment of Infarct Expansion by Echocardiography
Infarct expansion may be responsible for left
ventricular enlargement in the early stages after AMI,
and contribute to the ventricular remodeling in all stages.
This occurred in patients with large infarct area.
Ventricular remodeling after AMI is an important
process affecting ventricular function and survival.
Therefore, infarct expansion was the most powerful
predictor of high risk patients with ventricular
remodeling after AMI. Gaudron et al demonstrated that
infarct expansion was present in 50% of patients with
anterior infarctions,6 but only 7 of 44 anterior infarctions
had infarct expansion in our study. There were 26
patients of anterior AMI with initial dilatation but
without early reperfusion at entry, most of whom had
cardiac events. Thus, we believed that increased ESAi
within 48 hours of onset of AMI can be considered an
echocardiographic manifestation of infarct expansion,
was suggested to be used as an early predictor for high
risk after AMI.
The relationship between reperfusion and
prognosis at the early stage after AMI. Early reperfusion
after AMI can reduce infarct area, prevent infarct
expansion and subsequent left ventricular dilatation. This
study demonstrated that there were 15 anterior AMI with
early reperfusion, 7 of whom had infarct expansion at
entry, infarct area decreased significantly at 2 weeks
after AMI, left ventricular size decreased and EF value
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increased markedly at 3 months (0.47±0.06 VS 0.53±
0.04, P<0.05). Thus, echocardiography can serially and
accurately assess dynamic changes of infarct expansion
and ventricular remodeling after AMI.
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Role of Signal-Averaged ECG in Predicting Results of Flecainide
Provocation Test Used in Family Screening for Brugada Syndrome
NGAI-SHING MOK, CHI-CHUNG CHOY, NGAI-YIN CHAN, AMY HO, SUET-TING LAU, YUEN-CHOI CHOI
From Cardiology Team, Department of Medicine & Geriatrics, Princess Margaret Hospital, Hong Kong
MOK ET AL.: Role of Signal-Averaged ECG in Predicting Results of Flecainide Provocation Test Used in Family
Screening for Brugada Syndrome. Brugada syndrome (BS) is an inherited arrhythmogenic disease with an autosomal
dominant mode of inheritance. Flecainide provocation test (FPT) has been shown to be highly sensitive and specific
in unmasking the Brugada ECG pattern in affected subjects. We sought to test if late potential (LP) in signalaveraged electrocardiogram (SAECG) is helpful in predicting the results of FPT used in family screening for BS.
The study included 17 asymptomatic Chinese subjects from 8 families (M:F 10:7, mean age 24.8±11.4 years) who
have undergone family screening for BS. All screened subjects had a normal 12-lead ECG at baseline. None had
structural heart disease. SAECG using a time domain analysis was recorded prior to the FPT. LP is defined as
positive when at least 2 of the 3 criteria are met: (1) filtered QRS duration >114ms; (2) root-mean square voltage of
terminal 40ms of QRS 20µV; (3) low-averaged signal <40µV of terminal QRS 38ms. Seven subjects had a
positive LP on SAECG. Among them 3 had a positive FPT. As for the 10 subjects with a negative LP, none had a
positive FPT. Thus in predicting the results of FPT among these subjects, LP on SAECG has a sensitivity, specificity,
positive predictive value and negative predictive value of 100%, 76.9%, 42.8% and 100% respectively. Conclusion:
LP on SAECG has a high sensitivity and negative predictive value in predicting results of FPT used in family
screening for BS. (J HK Coll Cardiol 2002;10:105-108)
Brugada syndrome, flecainide, signal-averaged electrocardiography, ST-segment elevation
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Introduction

positive and negative predictive values of SAECG in
predicting the results of FPT are calculated.

Brugada syndrome is a genetically determined
primary electrical disease characterized by a marked
S T - s e g m e n t e l e v a t i o n i n l e a d s V 1- V 3 o n
electrocardiogram (ECG) during sinus rhythm and a
propensity for life-threatening ventricular tachyarrhythmias. 1 Flecainide provocation test (FPT) has
been shown to be highly sensitive and specific in
unmasking the Brugada ECG pattern in subjects with a
concealed form of the disease2 and therefore frequently
used in family screening for the syndrome. Late
potential on signal-averaged electrocardiogram
(SAECG) is frequently recorded in patients with
Brugada syndrome3 but only rarely found among healthy
subjects. We therefore sought to study if SAECG is
helpful in predicting the results of FPT used in family
screening for Brugada syndrome in our local Chinese
population.

Methods
In Princess Margaret Hospital (PMH), FPT has
been used to identify Brugada syndrome among family
members of symptomatic patients with the syndrome if
their baseline ECG is normal or non-diagnostic. SAECG
using a time domain analysis is recorded and
echocardiogram performed. This is followed by a
FPT if no structural heart disease is found on
echocardiogram. LP is defined as positive when at least
2 of the 3 criteria are met: (1) filtered QRS duration
>114 ms; (2) root-mean square voltage of terminal
40 ms of QRS 20 µV; (3) low-averaged signal <40
µV of terminal QRS 38 ms. After an informed consent
is obtained, FPT is performed in Cardiac Care Unit
under continuous cardiac monitoring. Flecainide at a
dosage of 2 mg/kg (maximum 150 mg) is given
intravenously over 10 minutes. Leads V1 and V2 are
recorded in the 2nd and 3rd intercostal spaces in addition
to the conventional 4th intercostal space which has been
shown to enhance the sensitivity of FPT.4 A positive
FPT is defined as occurrence of terminal R wave and
>1 mm ST segment elevation in leads V1-V3 following
flecainide infusion. Subjects with a positive FPT will
be monitored for 6 hours or until the ST segment in
leads V1-V3 returns to baseline. Sensitivity, specificity,

J HK Coll Cardiol, Vol 10

Results
From February 1999 to December 2001, a total
of 17 asymptomatic Chinese subjects (M:F 10:7) with
a mean age of 24.8±11.4 years have undergone family
screening for Brugada syndrome in PMH. They came
from 8 families. Each family had one proband member
suffering from Brugada syndrome (Ventricular
fibrillation in 5, recurrent syncope in 2 and
asymptomatic in 1). All 17 subjects had a normal 12lead ECG at baseline. None had structural heart disease
found on echocardiogram. Of these 17 subjects, 7 had a
positive LP on SAECG. Among these 7 subjects 3 had
a positive FPT (Figure 1A) while 4 had a negative FPT.
Among the 10 subjects with a negative LP, none had a
positive FPT (Figure 1B). Thus in predicting the results
of FPT among these subjects, LP on SAECG has a
sensitivity, specificity, positive predictive value and
negative predictive value of 100%, 76.9%, 42.8% &
100% respectively. Two subjects complained of
dizziness during flecainide infusion which rapidly
subsided upon completion of the test. Transient unifocal
ventricular premature beats were recorded in 1 subject.
No bradyarrhythmia or tachyarrhythmia was found in
any subject during FPT.

Discussion
Brugada syndrome is potentially life-threatening
disease. Symptomatic patients may have up to a 62%
chance of arrhythmia recurrence over a 4-year followup.5 As this syndrome is an inherited disease with an
autosomal dominant mode of inheritance, it is therefore
essential to screen their family members who may also
be affected and therefore predisposed to life-threatening
ventricular arrhythmias. Genetic data has linked this
syndrome to mutations in cardiac sodium channel gene
SCN5A in chromosome 3.6,7 However SCN5A mutation
can be found in only 15-25% of patients with this
syndrome.8 Genetic screening for SCN5A mutation is
therefore an insensitive test in family screening to
identify Brugada syndrome unless SCN5A mutation is
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Figure 1. Late potential (LP) on signal-averaged ECG (SAECG) predicting results of flecainide
provocation test (FPT) in family screening for Brugada syndrome (see text). (A) Positive FPT evidenced
by coved type ST-segment elevation (arrowheads) in leads V1-V2 following flecainide infusion in a subject
with a positive LP on SAECG (B) Negative FPT in a subject with a negative LP on SAECG.

already documented in probands. Moreover, genetic test
for channelopathies is expensive and not easily
accessible. Using 12-lead ECG to diagnose Brugada
syndrome among family members is easy if the typical
Brugada ECG pattern is found on their ECG during sinus
rhythm. However, dynamic changes or transient
normalization of the ST-segment may obscure the
correct diagnosis. Flecainide, a potent sodium channel
blocker, has been shown to be highly sensitive and
specific in unmasking the syndrome in affected subjects
who have normal baseline ECG. 2 It is therefore
frequently used locally9 and world-wide for the purpose
of family screening in Brugada syndrome.
LP on SAECG reflects conduction delay in the
ventricles. Although at present the role of conduction
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disturbance in the right ventricle in arrhythmogenesis
of the syndrome is a matter of some controversy, it is
well known that LP on SAECG is frequently found in
patients suffering from Brugada syndrome.3 LP can be
found among patients with Brugada syndrome
irrespective of whether the Brugada ECG pattern is
manifested or concealed. 10 Ikeda et al 11 studied LP
among patients with Brugada syndrome and found that
it can even be used as a noninvasive risk stratifier in
these patients. To date, there is as yet no study to
examine whether LP on SAECG is useful in family
screening for the syndrome. In this study, we were able
to demonstrate in this small cohort of subjects that LP
in SAECG has a 100% sensitivity and negative
predictive value in predicting the results of FPT. The
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clinical implication of these results is that in conducting
family screening for Brugada syndrome, we can start
by recording both 12-lead ECG and SAECG. If the 12lead ECG does not show any Brugada ECG pattern,
FPT should be followed to look for any concealed form
of the Brugada syndrome. But for those asymptomatic
subjects who are reluctant to undergo FPT which
requires venipuncture and intravenous drug infusion
under close cardiac monitoring, a negative LP on their
SAECG should reliably predict a negative FPT and FPT
might be spared. However, if a positive LP is found,
they should be strongly encouraged to undergo FPT.
This study has the following limitations. Firstly,
the number of tested subjects in this study is small.
Whether the results in this preliminary study apply to
family screening in all patients with Brugada syndrome
remains to be clarified in future study which should
include a larger number of subjects. Secondly, the
definitions of positive LP in SAECG and positive FPT
vary among different studies. The results of this study
are applicable only in situations where the current
definitions used in this study are adopted.

Conclusions
LP on SAECG has a high sensitivity and negative
predictive value in predicting the results of FPT used
in family screening for Brugada syndrome. SAECG
using a time domain analysis should be included as an
additional non-invasive diagnostic tool in family
screening for Brugada syndrome. Asymptomatic
subjects with a negative LP could be reassured absence
of the disease and FPT might be spared. However,
subjects with a positive LP should undergo FPT to look
for any concealed form of the syndrome.

J HK Coll Cardiol, Vol 10
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Safety and Feasibility of Diagnostic Coronary Angiogram as Day
Procedure
CHIU-LAI FU, MICHAEL KANG-YIN LEE, MIU-CHING CHAN, VIOLET LAU, SIU-FUNG YIU, KAM-TIM
CHAN, CHUNG-SEUNG CHIANG, KAU-CHUNG HO
From Division of Cardiology, Department of Medicine, Queen Elizabeth Hospital, Kowloon, Hong Kong
FU ET AL.: Safety and Feasibility of Diagnostic Coronary Angiogram as Day Procedure. With the miniaturization
of diagnostic coronary catheters and meticulous post-procedural nursing care, puncture site complications are
much reduced and patients can be mobilized earlier. Diagnostic coronary angiogram as a day procedure has been
practiced worldwide. It can shorten hospital length of stay while improving patient satisfaction. During a pilot
period of 6 months at Queen Elizabeth Hospital, Hong Kong, we showed that in selected patients, similar procedure
could be performed safely and more cost-effectively. (J HK Coll Cardiol 2002;10:109-113)
Coronary, cost-savings, day procedure, feasibility, safety
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Background
The concept of cardiac catheterization as
outpatient is not new. Its safety has been confirmed in
certain selected groups of patient. 1 The major
advantages of cost savings and time conservation were
attractive. The introduction of high-quality, smaller
catheters has played an important role in the
development of outpatient laboratory procedures
nowadays.
To shorten hospital length of stay and to improve
quality of care and patient satisfaction, increasing
number of cardiac procedures is being done on day-
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patient basis at Queen Elizabeth Hospital, Hong Kong.
This study aims to assess the safety and feasibility of
performing diagnostic coronary angiogram as day
procedure.

Methods
A pilot study was carried out at the Cardiac Day
Center of Queen Elizabeth Hospital, Hong Kong from
July to December 2001.
It was known that vascular complications such
as haemorrhage, haematoma and AV fistula formation,
pseudoaneurysm and arterial thrombosis might occur
following cardiac catheterization. The primary
responsibility of the medical and nursing staff is to
ensure proper patient selection and to prevent
postoperative complications that might be dangerous
and associated with patient discomfort. Therefore,
special guidelines for selection of day-cath patients,
nursing management for optimal care after cardiac
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catheterization were designed (Table 1).2
During this pilot study, patients undergoing
diagnostic coronary angiogram, with a view to ad hoc
angioplasty, done by 1-2 assigned operators were
assessed for suitability as day procedure. They will be
interviewed by CCU on-duty doctor on the day of
preparation. The nurse of the day center would explain
all the details of the day procedure and its after care to
the patients and their relatives. All suitable day patients
fulfilling the selection criteria and with none of the

exclusion criteria would be arranged as first or second
cases on day of procedure. The operator of the procedure
would decide after the angiogram whether the patients
were suitable for day procedure or not.
The patients were recruited if they had normal or
minor lesions, no active chest pain or symptoms of CHF,
easily palpable femoral arteries with no evidence of
peripheral vascular disease, adequate blood pressure
control for hypertensive patients, adequate diabetic
control for DM patients, independent activity of daily

Table 1. Nursing management
Immediately post-operative nursing management after cardiac catheterization
Back from cardiac catheterization lab at ___________, BP ________, P ____.
Size of catheter used 4/5/6 Fr.
Total heparin used ______ units.
Circulation and pulse of the affected L/R, Limb/arm is normal/impaired/absent.
Wound oozing: Y/N
Haematoma: Y/N
Chest pain: Y/N
Dyspnoea: Y/N
The head of the bed is elevated to 30 degree / not elevated during bed rest and sand bag is applied: Y/N
Patient resumes diet at _______ and fluid intake is encouraged if no contraindication.
If complication is detected, Dr. ___________ is informed at __________.
Rank and Name: _________________________
Ambulatory period
The patient is allowed to sit out and slowly mobilize after 4 hours of the procedure at _______, BP _________, and P ________.
Wound oozing: Y/N
Any complications: Y/N
Dr. ______________ is informed at ____________.
Advise on wound management and possible complications by _______________.
Rank and Name: __________________________
Discharge
Patient is discharged at ____________________(at least 6 hours after procedure) after checking the wound by
Dr. ____________________.
Information sheet on " wound management and complication" is given to him/her.
The patient is discharged alone/accompanied by __________________.

Rank and Name: ____________________________

J HK Coll Cardiol, Vol 10
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living, accompanied by family members or relatives
after discharge, and home with lift to floor. Those
patients were excluded if they had ad hoc angioplasty
procedure done, significant coronary artery lesions
requiring further treatment, active bleeding or known
bleeding tendency, marked renal impairment with
creatinine >200 umol/L, obvious dehydration, were on
warfarin, lived alone with poor social support, or lived
far away from hospital.
Sheaths were removed right after the procedure
by manual compression until haemostasis achieved.
Then a sandbag would be applied over the groin wound
for 2-4 hours. The patients started to ambulate 4 hours
later 3 and were discharged in 6 hours if wound
haemostasis was adequately achieved. Written
instructions detailing the wound care and backup
medical support were given prior to discharge. They
were advised to attend a follow-up session the next
morning for wound inspection. Any complications were
then recorded.

Results
Out of a total of 125 elective procedures done by
the assigned operator during this period, 84 were
excluded either because they had ad hoc angioplasty
procedure done or did not meet the inclusion criteria.
Of the 41 eligible patients, two requested to stay
overnight because of personal reasons and one was
admitted to ward when wound haemostasis could not
be achieved after 8 hours. As a result, a total of 38
patients with normal angiogram or minor CAD were
recruited. Twenty-one of them were males and 17
females. Their age ranged from 28 to 71 years (52.3,
mean). All of them had stable angina with positive stress
test. Four French sheaths were used in 32 patients, 5F
in 4 and 6F in 2. No heparin was given during the
procedure in 37 patients while 1000 units of heparin
were given in one. No major complications were
observed and no patients presented to the hospital again
the night after the procedure. Clinical follow up was
done the next day in all but two of the patients. Mild
bruises were observed in 6 patients but with no
haematoma, pseudo-aneurysm or AV fistula formation
and no major bleeding requiring blood transfusion was
seen. All patients were symptom free on subsequent
follow up (Table 2). All patients expressed satisfaction
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with early discharge without staying overnight in the
hospital. There was no readmission related to the
procedure.

Discussions
This pilot study shows that day-patient diagnostic
coronary angiogram can be safely performed if we can
identify certain patient subgroups with low risk
characteristics. It is especially true with the availability
of the new high-quality 4F catheters with bigger inner
lumen. These give similar opacification and torquability
compared to the 5F or 6F catheters (reported in an
abstract form in the coming Tenth Annual Scientific
Congress of the Hong Kong College of Cardiology) and
it is easier to handle the puncture site wound.
In a number of cardiac centers overseas and
locally, heparin is not routinely given during diagnostic
catheterization procedures. In our cohort of patients,
only one was given intra-arterial heparin injection
deemed necessary by the operator. It was not given in
37 of the 38 patients, with no increase risk of
thromboembolism. This also helps to achieve a better
wound haemostasis after the procedure.
It is worth mentioning that meticulous nursing
care with clear nursing management protocol is essential
to ensure the safety of the day procedure and adequate
haemostasis of the wound. Clear written instruction on
how to handle subsequent wound complications and
backup medical support greatly improves patient
confidence and satisfaction.
In the study, all patients were requested to come
back for wound inspection the next morning to
document the possible wound complications. They were
more willing to come back the next morning to staying
in hospital overnight. Two patients did not attend the
wound inspection session because of typhoon signal
number 8 and heavy rain the subsequent day. Both of
them were enquired through telephone. Provided with
such a low risk of wound complications, we believe the
next-morning-wound-inspection session is not
mandatory in future full-scale service as long as the
patients are given proper instructions of wound care
and channels to report any suspicions.
With such a limited number of patients recruited
in the study, a total of 66 days of hospitalization were
saved (assuming each patient stayed in hospital for 1.5
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Table 2. Characteristics, catheter size and incidence of post-cath. complication of 38 patients
Case no.

Sex

Age

Reason for
coro

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

M
M
F
M
M
F
F
F
F
F
M
F
F
M
M
M
F
M
M
M
M
F
F
F
M
M
M
M
M
F
F
F
F
M
F
M
M
M

45
42
58
67
52
57
49
68
50
64
32
28
51
65
51
57
68
54
71
43
61
50
48
65
51
53
53
64
38
57
60
62
52
58
53
62
53
32

+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
Chest pain
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
+ve TMT
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Time to
ambulate
(hr)
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

Time to
discharge
(hr)
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
5
6
6
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Size of
catheter
(Fr)
4
4
4
4
4
4
4
5
4
4
4
4
4
4
4
4
4
5
5
4
5
4
4
4
4
4
4
4
4
4
6
4
4
6
4
4
4
4

Unit of
heparin

Complications

Remarks

0
0
0
0
0
0
0
1000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Mild bruise
Mild bruise
Mild bruise
Mild bruise
Mild bruise
Bruise
-

Typhoon No. 8
Heavy rain
-
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days) while patient satisfaction was enhanced with early
discharge. This translates into a significant amount of
hospital cost savings.
With the demonstrated safety, feasibility, costeffectiveness and better patient satisfaction, we are
proposing full-scale implementation of day
catheterization as a routine for diagnostic coronary
angiogram and cardiac catheterization in properly
selected group of patients.

Conclusion
Diagnostic coronary angiogram as day-procedure
is safe, feasible and cost-effective in selected patients.
The risks are minimal. Early ambulation is safe after
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uncomplicated cardiac studies with 4-6F femoral arterial
catheters in elective catheterization.
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Percutaneous Revascularisation in Diabetic Patients with Coronary
Artery Disease
WAI-HONG CHEN, CHU-PAK LAU
From Division of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital,
Hong Kong
CHEN and LAU: Percutaneous Revascularisation in Diabetic Patients with Coronary Artery Disease. Diabetic
patients with coronary artery disease are associated with an unfavourable long-term outcome. Surgical
revascularisation on top of medical therapy has been shown to confer survival benefit in patients with mutivessel and
left main disease. With the emergence of the percutaneous approach of revascularisation, several clinical trials have
been conducted to compare these two modalities of treatment. Consistent results were demonstrated in the diabetic
subgroup that coronary artery bypass grafting is superior to balloon angioplasty in preventing late adverse cardiac
event. With the advancement of percutaneous technique using coronary stenting as the predominant mode of catheterbased revascularisation, the latest comparison trial showed that stenting is a comparable alternative but is associated
with a higher incidence of repeat revascularisation than bypass surgery. However, the debate is not yet settled
because of the promising results of platelet glycoprotein IIb/IIIa antagonists and drug-eluting stents in improving
the safety and efficacy of percutaneous intervention. It remains to be proven by ongoing clinical trials the best
revascularisation strategy for diabetics with multivessel coronary disease. (J HK Coll Cardiol 2002;10:114-119)
Coronary artery disease, diabetes mellitus, revascularisation

IIb/IIIa

Following randomised clinical trials (RCTs) in
the 70's that showed the benefits of coronary artery
bypass graft (CABG) over medical treatment alone
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in certain subsets of patients with multivessel
coronary artery disease (CAD) and left main stem
disease, CABG has been regarded as the "standard"
treatment for these patients. With improvements in
expertise and technology, percutaneous transluminal
coronary angioplasty (PTCA) evolves from the
treatment of simple, focal, proximally located lesions
in a single vessel to those complex anatomic subsets
previously tackled only by cardiac surgeons.
In the late 1980's, six RCTs were undertaken
to compare PTCA and CABG as the revascularisation
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procedure in patients with multivessel CAD. The
main results were consistent among the trials.
Mortality was not significantly different between the
two modalities of treatment (Figure 1). Fewer repeat
revascularisations and recurrent angina were
achieved by CABG. A trend of reduction of
myocardial infarction (MI) was seen in patients
undergoing PTCA. 1-6 However, there are two
exceptions to the overall trial results. The Bypass
Angioplasty Revascularization Investigation (BARI)
trial showed that treated diabetics had a distinct
survival advantage with CABG. The benefit was seen
6 months after randomisation and the survival curve
continued to diverge up to 7 years of follow-up.
Survival was 76.4% for the CABG group and 55.7%
for the PTCA group at 7 years (p=0.0011). 7 The

Emory Angioplasty Versus Surgery Trial (EAST)
also showed a trend of better survival among diabetics
treated with CABG. Eight-year survival was 75.5%
in the CABG group and 60.1% in the PTCA group.8

Poor Outcome of Diabetics After
Revascularisation
Diabetes mellitus is associated with the early
initiation and accelerated progression of coronary
atherosclerosis. Diabetics constitute a significant
proportion of patients requiring revascularisation for
the treatment of advanced coronary artery disease.
Patients with diabetes are at increased risk of adverse
outcome after PTCA. In the early era of balloon

Figure 1. Survival of diabetic patients with multivessel coronary artery disease after percutaneous
transluminal coronary angioplasty or coronary artery bypass graft surgery in randomized controlled trials.
BARI = Bypass Angiolasty Revascularization Investigation; CABG = Coronary Artery Bypass Graft; CABRI
= Coronary Angioplasty versus Bypass Revascularisation Investigation; EAST = Emory Angioplasty versus
Surgery Trial; ERACI = Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty
versus Coronary Artery Bypass Surgery in Multivessel Disease; GABI = German Angioplasty Bypass Surgery
Investigation; RITA = Randomised Intervention Treatment of Angina; PTCA = Percutaneous Transluminal
Coronary Angioplasty.
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angioplasty, diabetic patients had more in-hospital
mortality or myocardial infarction (MI) compared
with patients without diabetes. The long-term
outcome is also plagued by increased risk of
restenosis, contributing to greater rates of mortality,
MI, and repeat revascularisation.9,10
The presence of diabetes is also associated with
a higher event rate after CABG. 11 Diabetic patients
have more rapid disease progression in saphenous
vein grafts and in native vessels whether grafted or
not. 12 Diabetes is also an independent risk factor of
late mortality after CABG.13
Metabolic and haematologic derangements
contribute to the increased incidence of adverse
cardiac events after revascularisation in diabetics.14
Platelets are more often activated with increased
aggregability, enhanced secretion of vasoconstrictive
agents, and greater mitogenic activity. Fibrinogen,
factor VII and plasminogen activator inhibior-1 levels
are increased while antithrombin III activity is
reduced. Diabetes is associated with endothelial
dysfunction and excessive smooth muscle cell
proliferation and extracellular matrix formation.15
The reasons for the inferiority of PTCA
compared with CABG for coronary revascularisation
in diabetics are usually attributed to a high restenosis
rate, incomplete revascularisation, and progression
of atherosclerosis. Improvements in the techniques
of both percutaneous and surgical techniques have
made it necessary to re-examine this issue from time
to time. This is especially true for percutaneous
intervention as changes in practice are occurring
rapidly over the last few years.

Stenting: Improvement
over Balloon Angioplasty
Balloon angioplasty is largely replaced by
coronary stent implantation as the predominant
modality of percutaneous revascularisation because
of the advantages of reduction in emergency CABG
and restenosis.16,17 CABG has also undergone changes
with the routine use of arterial conduits that has better
long-term patency.18 The Arterial Revascularization
Therapy Study (ARTS) was undertaken to compare
contemporary percutaneous and surgical
revascularisation for the treatment of patients with
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multivessel CAD. In the diabetic subgroup, the 1year incidence of the individual components or the
composite of death, MI, or stroke was similar between
the two groups. The main difference was the
increased need for repeat revascularisation in the stent
group (14.3% vs 3.1%; p <0.001). 19 Although the
reintervention rate has been reduced by ~50%
compared with balloon angioplasty results in prior
comparison trials, coronary stenting in diabetics is
still associated with a high rate of restenosis and the
resulting need for repeat revascularisation,
confirming the results of retrospective series which
reported poorer outcomes of diabetics after stent
implantation compared to nondiabetics.20,21 Moreover,
the mortality was 6.4% for the stent group and 3.1%
for the surgery group, although not reaching
statistical significance. From the BARI and EAST
experience, a longer follow-up may unmask the
mortality difference between the two groups.

Platelet Glycoprotein IIb/IIIa
Antagonist: Reduction in Mortality
and Repeat Revascularisation
Another important advance in percutaneous
revascularisation emerges from the use of platelet
glycoprotein (GP) IIb/IIIa antagonists. In particular,
abciximab has been shown to reduce ischaemic
cardiac events following balloon angioplasty,
artherectomy, and stent implantation. 22-24 In the
Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
Trial (EPISTENT) diabetic substudy, the 6-month
target vessel revascularisation (TVR) rate was
significantly reduced from 16.6% in the stent-placebo
group to 8.1% in the abciximab-stent group. 25
Angiographic analysis showed a significant decrease
in the late loss index. The data are suggesting an antirestenotic effect of abciximab which may be related
to its non-specific inhibitory effects on integrin
receptors including IIb/IIIa, αv β3 and Mac-1, which
have been implicated in the thrombotic and
proliferative response leading to neointima formation
after arterial injury.26-29 In addition to TVR reduction,
evidence of mortality reduction was observed in the
EPISTENT trial when abciximab was used as adjunct
during coronary stenting. 30 Meta-analysis of
Evaluation of 7E3 for the Prevention of Ischemic
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Complications (EPIC), Evaluation in PTCA to
Improve Long-term Outcome with abciximab GP IIb/
IIIa blockade (EPILOG), and EPISTENT
demonstrated a survival benefit in diabetic patients
receiving abciximab during elective or urgent
percutaneous intervention. A 44% mortality reduction
at 1 year from 4.5% to 2.5% was found. 31 The
combination of abciximab and stenting should be
considered in diabetic patients undergoing
percutaneous revascularisation because of the
significant reduction in mortality, MI and reintervention and should be adopted for future
comparison trials.

Drug-eluting Stents: Reduction of
Restenosis; Complete Revascularisation
Enormous efforts have been invested in the
attempt to reduce restenosis soon after the inception
of PTCA. Among the numerous devices and drugs
that have been tested, stents were shown in the early
1990s to be the first device capable of reducing
restenosis compared with balloon angioplasty. The
improved but still disappointing rate of in-stent
restenosis (ISR) especially in diabetic patients was
the impetus for continued effort to overcome this
enemy of percutaneous revascularisation. Although
proven to be an effective treatment for ISR, vascular
brachytherapy was disappointingly unsuccessful in
diminishing restenosis when applied to de novo
lesions after coronary angioplasty or stenting. 32
Following early promising results of reduction in
restenosis in animal models, 33-35 a pilot study with
the sirolimus-eluting stent was shown to achieve 0%
ISR up to 1-year angiographic follow-up in 29
patients.36 The dramatic result of ISR reduction was
recently joined by the Randomised double-blind
study with the Sirolimus-eluting Bx VElocity
balloon expandable stent in the treatment of patients
with de novo native coronary artery lesions (RAVEL)
which showed again no ISR at 6 months in patients
receiving sirolimus-eluting stents. The diabetic
subgroup in RAVEL is no exception to this
remarkable anti-restenotic effect of sirolimus. The
ISR was 0% in the sirolimus-eluting stent group
versus 42% in the bare stent group. 37 Many other
medications including paclitaxol and actinomycin-
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D are being tested in clinical trials of drug-eluting
stents. The TAXUS I trial using paclitaxol-eluting
NIR stents also demonstrated a promising 0%
ISR. 38 When the safety and efficacy are confirmed
by longer-term follow-up, the new era of
percutaneous revascularisation will begin. Small
vessels, long lesions, bifurcations, and unprotected
left main stenosis can be confidently tackled by drugeluting stents with little hindrance from the worry of
restenosis. A more complete revascularisation
comparable to CABG may be achieved by the
percutaneous approach. With development in the
technology of detecting vulnerable plaques, 39 e.g.
optical coherence tomography, thermography,
elastography, those haemodynamically insignificant
but unstable lesions may be prophylactically stented
for the prevention of future coronary events from
plaque disruption.

Conclusion
Advances in interventional cardiology will
most likely impact upon the shortcomings of catheterbased revascularisation in diabetics. Equipped with
GP IIb/IIIa antagonists and drug-eluting stents,
interventional cardiologists are ready again for
another comparison trial with CABG. The ARTS-2
is underway to compare percutaneous revascularisation
incorporating these improvements with CABG in
patients with multivessel disease. The best
revascularisation strategy for diabetic patients with
multivessel CAD remains to be elucidated by ongoing
clinical trials.
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ECG Quiz
CHI-CHIU KUM, WING-HONG FUNG
From Division of Cardiology, Department of Medicine & Therapeutics, Prince of Wales Hospital,
Hong Kong

A 17-year-old boy attended Accident and
Emergency Department because of palpitation. He
described as fast and regular heart beats. There was no
associated dizziness. He had experienced intermittent
fast palpitations for few months, but never as severe as
this time. Otherwise he enjoyed good past health and
he had no history of syncope. Family history was
unremarkable. He was hemodynamically stable and
fully conscious. A 12-lead electrocardiogram (ECG)
was performed immediately (Figure 1).

The patient was admitted to coronary care unit (CCU).
The tachycardia was aborted when the patient was
admitted to CCU. A 12-lead ECG was repeated and
shown in Figure 2. It showed delta waves and the
diagnosis of Wolff-Parkinson-White Syndrome was
made. Electrophysiology study confirmed the presence
of right free wall accessory pathway and radiofrequency
ablation was performed. There was no recurrence of
symptoms for six months after the procedure.

Question
What is the ECG diagnosis?
A)
B)

C)

monomorphic ventricular
tachycardia (VT)
supraventricular tachycardia
(SVT) with aberrant
conduction
SVT with anterograde
conduction over an accessory
atrioventricular pathway

Figure 1.

Figure 2.
J HK Coll Cardiol, Vol 10

July 2002

120

ECG QUIZ

Answer: C

The second step is to differentiate VT from
antidromic SVT. There are three questions:

Discussion
1.
It is always a difficult clinical task to have a
correct ECG diagnosis for regular wide complex
tachycardia. Differential diagnoses include VT, SVT
with aberrant conduction and SVT with anterograde
conduction over an accessory atrioventricular pathway
(antidromic SVT). Differentiation among these is
important because the immediate management is
different. However, fast and reliable method is not
always available. We adopted the stepwise approach
suggested by Antunes et al published in September 1994
in PACE Vol. 17.1
The first step aims to differentiate VT or
antidromic SVT from SVT with aberrant conduction.
There are four questions:
1.

2.

3.

4.
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Absence of an RS complex in all precordial leads?
If the answer is yes, it suggests VT or antidromic
SVT. If not, go to question 2.
Onset of R to nadir of S interval >100 ms in 1
precordial lead? If the answer is yes, it suggests
VT or antidromic SVT. If not, go to question 3.
More QRS complexes than P waves? If the answer
is yes, it suggests VT or antidromic SVT. If not,
go to question 4.
Classic morphology criteria for VT present in leads
V1 and V6 (i.e. R, qR, QR or RS in V1; R:S ratio
<1 in V6 if frontal axis showed left axis deviation;
qR or QS in V6 if left bundle branch morphology)?
If the answer is yes, it is VT or antidromic SVT. If
the answer is "no" again, VT or antidromic SVT
is excluded, and the diagnosis of SVT with aberrant
conduction is made.

2.

3.

Predominantly negative QRS complexes in the
precordial leads V4 to V6? If yes, it is VT. If the
answer is no, go to question 2.
Presence of a QR complex in one or more of the
precordial leads V2 to V6? If yes, it is VT. If the
answer is no, go to question 3.
AV relation different from 1:1? (More QRS
complexes than P waves?) If yes, it is certainly
VT. If the answer is no, VT is excluded and the
diagnosis of antidromic SVT is made.

The admission ECG of the patient showed RS
complex in V4 to V6. However, the R to S interval is
140 ms in V6. Based on step one, it suggested VT or
antidromic SVT. We proceeded to the second step. The
QRS complexes of V4 to V6 were predominantly
positive, and there was no QR pattern seen in V2 to V6,
and there was no atrioventricular dissociation identified.
The answers to all 3 questions in step 2 were "no". This
excluded ventricular tachycardia and the diagnosis of
antidromic SVT was suggested. Antidromic SVT with
anterograde conduction via right free wall accessory
pathway was inducible in electrophysiology study with
identical morphology as admission ECG.
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